TY - JOUR
T1 - Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study
AU - Falissard, Bruno
AU - Simpson, Eric L.
AU - Guttman-Yassky, Emma
AU - Papp, Kim A.
AU - Barbarot, Sebastien
AU - Gadkari, Abhijit
AU - Saba, Grece
AU - Gautier, Laurene
AU - Abbe, Adeline
AU - Eckert, Laurent
N1 - Funding Information:
Bruno Falissard has received consultancy honoraria from Actelion, Allergan, Almirall, Astellas, AstraZeneca, Bayer, Biotronik, BMS, Boeringer Ingelheim, Daiichi-Sankyo, Eli Lilly, Genzyme, Gilead, Grunenthal, GSK, HRA, Janssen, Lundbeck, MSD, Novartis, Otsuka, Pierre Fabre, Roche, Sanofi, Servier, Stallergene, UCB, and ViiV. Eric L. Simpson has received grants/research support from Amgen, Celgene, Chugai, Galderma, and Regeneron Pharmaceuticals, Inc., and is a consultant for Anacor, Asubio, Celgene, Galderma, Genentech, Medicis, and Merck. Emma Guttman-Yassky has acted as a consultant for and received grants/honoraria from AbbVie, Anacor, Celgene, Celsus Therapeutics, Dermira, Galderma, Glenmark, Janssen Biotech, LEO Pharmaceuticals MedImmune, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, Stiefel/GlaxoSmithKline, Vitae, Mitsubishi Tanabe, Eli Lilly, Asana Biosciences, Kiowa Kirin; has acted as an investigator for Celgene, Glenmark, LEO Pharmaceuticals, MedImmune, Regeneron Pharmaceuticals, Inc., Eli Lilly; and has participated in advisory boards for Celgene, Celsus Therapeutics, Dermira, Galderma, Glenmark, MedImmune, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, Stiefel/GlaxoSmithKline, Vitae and Asana Biosciences. Kim A. Papp has been a consultant and investigator for Akros, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb, Dermira, Dow Pharma, Genentech, Merck Serono, Mylan, Roche, Sanofi-Aventis/Genzyme, Takeda and UCB; a speaker, consultant, and investigator for AbbVie, Amgen, Astellas, Celgene, Eli Lily, Galderma, Janssen, Kyowa Hakko Kirin, LEO Pharma, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., and Valeant; an investigator for Allergan, Anacor, Coherus, GlaxoSmithKline, and MedImmune; a consultant for AstraZeneca, Baxter, CanFite, Meiji Seika Pharma, and Mitsubishi Pharma; and a speaker and consultant for Devonian. Sebastien Barbarot has received research grants from Pierre Fabre Laboratory and Fondation pour la dermatite atopique, and received personal fees from Bioderma, Laboratoire La Roche Posay, Sanofi-Genzyme, Abbvie, Novartis, Janssen, and LEO Pharma. Abhijit Gadkari was an employee of and stockholder in Regeneron Pharmaceuticals, Inc. at the time of the study, and is currently an employee of Boehringer Ingelheim. Grèce Saba and Laurène Gautier are employees of Kantar–Health Division, who received funding from Sanofi to conduct the non-US study. Adeline Abbe and Laurent Eckert are employees of and stockholders in Sanofi.
Funding Information:
The authors thank the patients, their families and all physicians involved in this study. The study, as well as the journal's Rapid Service Fee, was funded by Sanofi (Bridgewater, NJ, USA) and Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA). Medical writing support was provided by Saba Choudhary, PhD, of Prime (New York, USA), according to Good Publication Practice guidelines (Link) and was funded by Sanofi and Regeneron Pharmaceuticals, Inc. The authors were responsible for all content and editorial decisions, and received no honoraria related to the development of this publication. All authors had full access to all the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.
Funding Information:
The study, as well as the journal's Rapid Service Fee, was funded by Sanofi (Bridgewater, NJ, USA) and Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA).
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Introduction: Atopic dermatitis (AD) is an incurable, inflammatory skin disease characterized by skin barrier disruption and immune dysregulation. Although AD is considered a childhood disease, adult onset is possible, presenting with daily sleep disturbance and functional impairment associated with itch, neuropsychiatric issues (anxiety and depression), and reduced health-related quality of life. Although such aspects of adult AD disease burden have been measured through standardized assessments and based on population-level data, the understanding of the disease experienced at the patient level remains poor. This text-mining study assessed the impact of AD on the lives of adult patients as described from an experiential perspective. Methods: Natural language processing (NLP) was applied to qualitative patient response data from two large-scale international cross-sectional surveys conducted in the USA and countries outside of the USA (non-USA; Canada, France, Germany, Italy, Spain, and the UK). Descriptive analysis was conducted on patient responses to an open-ended question on how they felt about their AD and how the disease affected their life. Character length, word count, and stop word (common words) count were evaluated; centrality analysis identified concepts that were most strongly interlinked. Results: Patients with AD in all countries were most frequently impacted by itch, pain, and embarrassment across all levels of disease severity. Patients with moderate-to-severe AD were more likely than patients with mild AD to describe sleep disturbances, fatigue, and feelings of depression, anxiety, and a lack of hope that were directly associated with AD. Centrality analysis revealed sleep disturbance was strongly linked with itch. Collectively, these concepts revealed that patients with AD are impacted by both physical and emotional burdens that are intricately connected. Conclusions: Qualitative data from NLP, being more patient-centric than data from clinical standardized measures, provide a more comprehensive view of the burden of AD to inform disease management.
AB - Introduction: Atopic dermatitis (AD) is an incurable, inflammatory skin disease characterized by skin barrier disruption and immune dysregulation. Although AD is considered a childhood disease, adult onset is possible, presenting with daily sleep disturbance and functional impairment associated with itch, neuropsychiatric issues (anxiety and depression), and reduced health-related quality of life. Although such aspects of adult AD disease burden have been measured through standardized assessments and based on population-level data, the understanding of the disease experienced at the patient level remains poor. This text-mining study assessed the impact of AD on the lives of adult patients as described from an experiential perspective. Methods: Natural language processing (NLP) was applied to qualitative patient response data from two large-scale international cross-sectional surveys conducted in the USA and countries outside of the USA (non-USA; Canada, France, Germany, Italy, Spain, and the UK). Descriptive analysis was conducted on patient responses to an open-ended question on how they felt about their AD and how the disease affected their life. Character length, word count, and stop word (common words) count were evaluated; centrality analysis identified concepts that were most strongly interlinked. Results: Patients with AD in all countries were most frequently impacted by itch, pain, and embarrassment across all levels of disease severity. Patients with moderate-to-severe AD were more likely than patients with mild AD to describe sleep disturbances, fatigue, and feelings of depression, anxiety, and a lack of hope that were directly associated with AD. Centrality analysis revealed sleep disturbance was strongly linked with itch. Collectively, these concepts revealed that patients with AD are impacted by both physical and emotional burdens that are intricately connected. Conclusions: Qualitative data from NLP, being more patient-centric than data from clinical standardized measures, provide a more comprehensive view of the burden of AD to inform disease management.
KW - Atopic dermatitis
KW - Natural language processing
KW - Patient perception
KW - Qualitative
KW - Text-mining
UR - http://www.scopus.com/inward/record.url?scp=85078951209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078951209&partnerID=8YFLogxK
U2 - 10.1007/s13555-020-00356-0
DO - 10.1007/s13555-020-00356-0
M3 - Article
AN - SCOPUS:85078951209
SN - 2190-9172
VL - 10
SP - 297
EP - 305
JO - Dermatology and Therapy
JF - Dermatology and Therapy
IS - 2
ER -